[Effects of combined treatment of infantile toxoplasmosis with pyrimethamine (daraprim) and sulfonamides on the blood and bone marrow].
D000380:Agranulocytosis / Q000209:etiology; D000748:Anemia, Macrocytic / Q000209:etiology; D004357:Drug Synergism; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011739:Pyrimethamine / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy*; D015002:Yeast, Dried / Q000494:pharmacology*
D005493:Folic Acid Antagonists; D013449:Sulfonamides; D011739:Pyrimethamine
Auswirkungen kombinierter Behandlung der kindlichen Toxoplasmose mit Pyrimethamin (Daraprim) und Sulfonamiden auf Blut und Knochenmark.